Option chain shows key data for Aprea Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Aprea Therapeutics.

Aprea Therapeutics (NASDAQ:APRE) Stock, Option Chain

APREA THERAPEUTICS INC

Aprea Therapeutics

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

pharma lab worker ai

Biotech

Equities

News

Financing

Movers

Trading Ideas

General

APRE

FDA clearance for Aprea Therapeutics&#39; APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund clinical development and ensure company sustainability until 2026.

Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?

Long Ideas

Penny Stocks

Small Cap

Insider Trades

Pre-Market Outlook

Markets

ERAS

STSA

The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying

Offerings

Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading lower by 17.59% to $5.20 after the company announced pricing of a $5.5 million underwritten public offering of common stock.

What Else?

Why Aprea Therapeutics Shares Hit A New 52-Week Low Today

Aprea Therapeutics Inc

Press Releases

Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

Health Care

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Earnings

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Legal

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Contracts

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

IART

OMGA

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AIM ImmunoTech

Apollomics Inc. - Class A Ordinary Shares

Apollomics

BioCardia

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Eterna Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

HCW Biologics

HOOKIPA Pharma

Immuron Limited - American Depositary Shares

Immuron

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Kairos Pharma

Moleculin Biotech

Marker Therapeutics

MetaVia

Mainz Biomed

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

PharmaCyte Biotech

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Spruce Biosciences

Turnstone Biologics

HC Wainwright & Co.

Wedbush

Maxim Group

Comments

Aprea Therapeutics

Aprea Therapeutics (APRE) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga